Search Results for: 43

— Issuance of New Patent and Allowance of Patent Application Diversifies SYN-010 Protection in US — ROCKVILLE, Md., Sept. 26, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office […]

— Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients — — Conference Call Today, August 8, 2019, at 4:30 p.m. (ET) — ROCKVILLE, Md., Aug. 8, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company

— Conference Call Scheduled for Thursday, August 8, 2019 at 4:30 p.m. ET — ROCKVILLE, Md., Aug. 1, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights

— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 — — Conference Call Wednesday, February 27, 2019, at 4:30 p.m. (EST) — ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a clinical-stage company developing therapeutics that preserve

— Announced Agreement with Cedars-Sinai Medical Center to Co-fund a Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C — — Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs — — Conference Call Today, November 8, 2018, at 4:30 p.m. (EST) — ROCKVILLE, Md., Nov. 8, 2018 /PRNewswire/ — Synthetic Biologics,

— SYN-004 End of Phase 2 Meeting with U.S. Food & Drug Administration on Track for Third Quarter of 2018 — — Conference Call Today, August 8, 2018, at 4:30 p.m. (EDT) — ROCKVILLE, Md., Aug. 8, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome

ROCKVILLE, Md., Aug. 1, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share

— Preliminary Agreement Reached with FDA on Proposed Phase 3 Clinical Trial Synopsis for SYN-004 (ribaxamase) — — Conference Call Today, May 8, 2018, at 4:30 p.m. (EDT) — ROCKVILLE, Md., May 8, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore

— Company Provides Update on Late-stage Microbiome-focused Product Candidates — — Conference Call Today, February 22, 2018, at 8:30 a.m. (EST) — ROCKVILLE, Md., Feb. 22, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided a

ROCKVILLE, Md., Jan. 2, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steven Shallcross, Interim CEO & CFO, is scheduled to present at the Biotech Showcase™ 2018 Conference next week in San Francisco, as